Morrisville, NC, USA / Billingham, UK - June 1, 2011: Fujifilm Diosynth Biotechnologies
is expanding its existing contract manufacturing capabilities with the addition of a 1,000L
Xcellerex® Single-Use Bioreactor to its RTP, North Carolina facility. This expansion
reinforces the commitment to lead the global Biologics CMO industry through continuous
innovation and implementation of new technologies, service delivery and quality, as
announced by Japan-based parent company, FUJIFILM Corporation.
The addition of the 1,000L single-use bioreactor, single-use mixers, and single-use
harvest filtration will supplement existing seed train and purification equipment as part of
a hybrid implementation approach. This project is the continuation of an on-going cell
culture capacity expansion by Fujifilm Diosynth Biotechnologies. This addition
complements the 200L Xcellerex single-use bioreactor already in operation at the
company’s Process Development Laboratories in Cary, NC, and the existing 2,000L
stainless steel train located in the RTP, NC cGMP manufacturing plant.
“Single use technologies are uniquely suited for multi-product contract manufacturing
with the added advantage that the operations are easily transferable between sites and
are easily expandable for increased supply needs” said Stephen Spearman, President of
Fujifilm Diosynth Biotechnologies USA. The XDR-1000 can be operated at working
volumes ranging from 200- 1,000L. “The flexibility of scale will allow us to better serve
the demands of companies requiring material for pre-clinical studies, early to mid-phase
clinical production and beyond,” added John Foy, Senior Director of Business
Development and Logistics at Fujifilm Diosynth RTP.
About Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies (www.fujifilmdiosynth.com) is an industry-leading
Biologics Contract Manufacturing Organization with locations in Research Triangle Park,
North Carolina, USA and Billingham, United Kingdom. Fujifilm Diosynth has over twentyfive
years of combined experience in the development and manufacturing of
recombinant proteins, vaccines, monoclonal antibodies, among other large molecules
expressed in a wide array of microbial, mammalian, and insect systems. The company
offers a comprehensive list of services from cell line development using its proprietary
pAVEway™ system to process development, analytical development, clinical and
commercial manufacturing. Both sites are FDA-approved for the production of
commercial products.
For additional information please contact Jennifer Kohm at: (919) 337-4248 or Bridget
Hall at +44 1642 367320.
